Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Material +

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

By The Northwire Desk — AI Analysis Apr 01, 2026 · 08:02 QNTM · 6.65 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Quantum BioPharma submitted a formal Investigational New Drug (IND) application to the FDA for Lucid‑21‑302 (Lucid‑MS), its first‑in‑class multiple sclerosis therapy.
  • The IND submission clears the path for initiating a Phase 2 clinical trial in Q2 2026, with interim data expected by Q4 2026.
  • The company highlights the large global MS market opportunity (≈ $38 billion by 2030) and positions Lucid‑MS as a differentiated neuroprotective approach targeting demyelination.

Key Details

  • IND Submission: Filed March 2026; includes non‑clinical pharmacology, toxicology, manufacturing, and quality data.
  • Regulatory Timeline: FDA response anticipated Q2 2026; Phase 2 trial planned to start Q2 2026 pending clearance.
  • Phase 1 Results: Completed; demonstrated safety and tolerability in healthy participants.
  • Planned Phase 2 Trial: Will evaluate efficacy, safety, and tolerability of Lucid‑MS in MS patients; interim data projected for Q4 2026.
  • Therapeutic Innovation: First‑in‑class mechanism aimed at inhibiting demyelination rather than immune modulation.
  • Market Opportunity: ≈ 2.8 million MS patients worldwide; market forecast > $38 billion by 2030 (Grand View Research).
  • Executive Quote – Dr. Andrzej Chruscinski: Emphasized comprehensive preclinical package and commitment to advancing the IND toward clinical evaluation.
  • Executive Quote – Zeeshan Saeed (CEO): Stated the IND submission as a key milestone for shareholder value creation and highlighted synergy with consumer‑health product UNBUZZD™ for sustainable cash flow.

Notable Quotes

“The submission of our IND marks an important milestone in the advancement of Lucid‑MS into clinical development for multiple sclerosis… This milestone reflects our commitment to shareholder value creation through disciplined investment in high‑potential therapeutic programs.” – Zeeshan Saeed, CEO, Quantum BioPharma

All forward‑looking statements are subject to risks and uncertainties detailed in the company’s full press release.

Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other